Daniel Timmermann

Lundbeck is set to acquire Longboard Pharmaceuticals for $2.6Bn, gaining access to bexicaserin - a selective 5-HT2C receptor agonist in development for Dravet syndrome, Lennox-Gastaut syndrome and other developmental and epileptic encephalopathies (DEEs). Bexicaserin has shown promising anti-seizure reduction in preclinical and clinical studies and is now being evaluated in a global Phase III clinical program. This strategic deal highlights increasing M&A activity in the CNS therapy area and renewed interest in serotonergic drug development. #Bexicaserin #Neuroscience #Epilepsy https://lnkd.in/e7BYFK8h

4

Lundbeck, an innovator within CNS disorders and Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven discovery platform, today announced the companies have entered into a strategic research collaboration to focus on discovery of a small molecule therapeutic for the treatment of migraine. The agreement includes an upfront payment, performance-based milestones, and royalties. “Iambic’s state-of-the-art platform - including the NeuralPLexer protein-ligand structure prediction technology - will accelerate the generation of novel candidates with a higher probability of success at reaching our patients,” said Tarek Samad, PhD, Senior Vice President, and Head of Global Research at Lundbeck. “The pace at which Iambic can both design molecules in silico and then test them in the laboratory has the potential to unlock compelling neurology targets that have eluded traditional drug discovery methods.” “We welcome the opportunity to work with industry leaders at Lundbeck and to demonstrate the potential of the Iambic platform to discover neurological medicines,” said Thomas Miller, Ph.D., Chief Executive Officer, and co-founder of Iambic. Iambic is also developing an internal pipeline of candidates, discovered using its platform that integrates AI models for protein structure prediction and wholistic drug design with high-throughput chemistry and biology experimentation. Iambic’s pipeline currently includes IAM1363, a highly selective, brain penetrant small molecule inhibitor of both wild-type and oncogenic HER2 mutants currently in a Phase 1/1b study, as well as a potential first-in-class selective dual CDK2/4 inhibitor for multiple cancer indications, an allosteric inhibitor for KIF18A, and additional new programs. This partnership reflects Lundbeck’s strong commitment to innovation across R&D. Merging the power of generative AI with expertise in developing drug candidates for brain diseases aims to significantly enhance the probability of success and reduce discovery timelines for novel therapeutics. The partnership also supports Lundbeck’s strategy of being a focused innovator in brain health. #AI #MachineLearning #Innovation #DrugDiscovery  #CNS #BrainHealth #Migraine #Partnership #Iambic #Lundbeck 

37

Schedule a meeting with Tim Sharpington at BIO-Europe 2024 in Stockholm to discuss the future of precision microbiome therapies in immuno-oncology and inflammatory bowel disease.🤝 https://lnkd.in/dRGyPtmn We’re actively seeking partnerships with investors and collaborators to drive the next stage of our clinical and commercial growth. Learn about the latest progress in our pipeline: MELODY-1: Our international Phase 1b trial of MB097 in advanced melanoma, combining with MSD’s KEYTRUDA® (pembrolizumab). We’ve just dosed the first patient in this cutting-edge trial targeting patients who haven't responded to existing immunotherapies. COMPOSER-1: Our Phase 1b trial of MB310 in ulcerative colitis, aiming to revolutionizse outcomes bring new, safe and potentially disease modifying treatment options for patients with inflammatory bowel disease through microbiome-based therapies. Let’s connect and explore how we can collaborate to bring these innovative treatments to patients. 🤝 Schedule a meeting with Tim: https://lnkd.in/dRGyPtmn 🔗 #BIOEurope2024: https://lnkd.in/dnuNZ2D #Biotech #Pharma #Innovation #Microbiome #Oncology #CancerResearch #IBS Informa Connect Life Sciences

47

Two of our IO Biotech co-founders—CCIT - Center for Cancer Immune Therapy, Denmark Inge Marie Svane, MD, PhD, and Mads Hald Andersen, DMSc, PhD —recently had their publication, "State-Of-The-Art Advancements on Cancer Vaccines and Biomarkers" published in the American Society of Clinical Oncology (ASCO) Educational Book.   Read about the latest advancements in cancer vaccines, including the strategy behind IO Biotech's novel immune-modulating therapeutic vaccine and its potential for transforming the lives of cancer patients: https://lnkd.in/eQCvt3b8

70

2 Kommentarer

Part 3 of 3. A short interview with Redeye about the next steps for SCO-101 and Scandion Oncology.

18

Congratulations David Baker, John Jumper and Demis Hassabis on winning the 2024 The Nobel Prize in Chemistry 👏👋🥇🥇!! In particular Congratulations from the bottom of my heart to Demis who is both an incredible scientist and entrepreneur as well as an incredible human being whom I have had the pleasure and privilege to know personally since 2 decades, amply deserved and truly inspiring accolade to complement a trajectory hard if not impossible to replicate by anybody that I know. I can remember vividly nearly 2 decades ago when Demis first told me over lunches and discussions about his mindblowing ideas for the future and what became Google DeepMind (congratulations DeepMind!!), as inspiring and mindblowing then as he is now, and then seeing the AI revolution take shape in part propelled by his inspiring leadership. This is superlative and outstanding news for AI (building on yesterday’s news on the Physics Prize) and truly outstanding and superlative news for the AI+bio sector, academically and industrially (all companies in the AI and AI+bio sectors just got a huge instantaneous value boost!), and is the best proof and example that AI has the potential to completely revolutionise the way and pace in which science and medicine and generally societal progress can be achieved. For academic science the fact that both the #NobelPrize in Physics and in Chemistry this year came from work done largely in big companies like Google and DeepMind is an important, humbling watershed moment, as it shows beyond doubt that the best science can & will increasingly be done in industry *not academic publicly funded labs* unless something fundamental changes in how academic science funding & structures work. As societies we depend on free academic science (as in science that can take place with total academic freedom) for our survival and progress, and so this week’s news must serve both as inspiration and a stark reminder that time has come for academic science to evolve together with industrial science and change its ways for the better. Outstanding news! #AI #artificialintelligence #NobelPrize #NobelChemistryPrize #NobelPhysicsPrize #AIbio #machinelearning #ml #datascience #biomedicine #medicalresearch

14

3 Kommentarer

Else Marit Inderberg and Sébastien Wälchli from Oslo University Hospital explore what we need to know about T cells successfully fighting #CancerPrevention Cell-based immunotherapy uses the patient’s own immune cells to target and kill cancer cells in a specific manner. #Lymphocytes called T cells are mainly used for this type of therapy, and to target them more efficiently against cancer cells, they are genetically modified to express chimeric antigen receptors (CAR) or T cell receptors (TCR) that bind #proteins or peptides presented on the surface of cancer cells. There are currently six CAR T cell therapies approved for the treatment of #blood cancers. However, none of these cellular therapies are yet available outside clinical studies for solid #cancers. Find out more here: #TCells #CancerTherapy https://bit.ly/3yQWClh

30

In this recent article published in Outsourcing Pharma, Cognizant’s Orla Cussen describes how she advanced through her career and the challenges and triumphs she encountered along the way. Her advice for young women with an interest in science is to seek out mentors and role models for inspiration and guidance, and not to be afraid to ask for help. Are you a female leader working in this industry - what would your advice be? Access the full article here: https://lnkd.in/gFdcbTEK #careerinpharma #womeninengineering #inspiring

184

10 Kommentarer

We are excited to welcome NordicRWE, the first Norwegian company to join the AstraZeneca BioVentureHub, integrated in the Gothenburg R&D site. NordicRWE, is an emerging company specializing in real-world evidence (RWE) generation. NordicRWE's focus on real-world evidence analytics and insights aligns seamlessly with the industry's growing demand for data-driven decision-making. By leveraging Nordic real-world data and advanced analytics and cutting-edge methodologies, NordicRWE is developing solutions that support data-driven drug development. Please read the news post here: https://lnkd.in/duN5c74R! Welcoming NordicRWE is exciting, not only because of the interesting technology with a solution to utilize the Nordic health data infrastructure, its alignment with AstraZeneca's vision around data-driven drug development, but also because NordicRWE is the first Norwegian company to join the AstraZeneca BioVentureHub community. This is the first evidence of the fruitful work of creating and deepening relationships within our ecosystems. The relationships between Oslo Cancer Cluster, Oslo Science City, and AstraZeneca BioVentureHub  have been cultivated for some years, with great support from academic groups, life science industry partners and public officials, and not least our dear colleagues at AstraZeneca Norway. The aim is to facilitate Norwegian startups’ access to residency at our BioVentureHub in the strategic AstraZeneca R&D site in Gothenburg. Simultaneously, Swedish companies will have the opportunity to reside at Oslo Cancer Cluster and collaborate closely with their environments in cancer and precision medicine. We look forward to welcoming the NordicRWE team, and more collaborations opportunities with and from Norway to follow. #NordicRWE #NewCompany #GrowingInnovationTogether #Ecosystem #BioVentureHub #OCC #OSC #AstraZeneca #Norway #Gothenburg #Oslo #NordicHealthData #RealWorldEvidence #WarmWelcome #DareToShare #Culture #Collaboration #MoU Hyggelig! Takk till Christian Jonasson, Steinar Thoresen, Christine Wergeland Sørbye, Ketil F. Widerberg, Guro Bjøntegaard, Caroline Lauritzen McAlpine, Robert Roth, Ulrika Edvardsson, Magnus R. Björsne, PhD, MBA, Assoc. Prof., Anders Persson, Pernilla Isberg, Emma Wiesel, Robert Börjes, Emelie Antoni Nina Mian, Yorick Kamlag, and more, who participated.

40

Company creation, metabolic diseases, and AI-powered drug discovery are amongst the hottest trends in 2024. #lifescience #hottesttrends2024 #aipowered #drugdiscorvery #companycreation #metabolicdiseases  https://lnkd.in/dTndXpMH

1

Vaccine Milestone: FDA Grants Priority Review to Bavarian Nordic’s Chikungunya Vaccine BLA The FDA has granted priority review to Bavarian Nordic's Biologics License Application for its chikungunya vaccine candidate, CHIKV VLP, a virus-like particle-based vaccine for individuals aged 12 and older. With a decision expected by February 2025, this accelerated review could lead to the first approved vaccine for chikungunya virus, a mosquito-borne disease affecting over 100 countries. The European Medicines Agency is also assessing the vaccine for potential approval by mid-2025. CHIKV VLP's single-dose format and promising clinical trial results reflect Bavarian Nordic's expertise and could provide a critical tool in combating global outbreaks and reducing the long-term effects of chikungunya. For more details please click the link! https://lnkd.in/dQWGZvy4 #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical 

2

We are pleased to share that our CPa9-HNE blood-based biomarker assay has received a Letter of Support from the FDA. CPa9-HNE, also known as the Nordic Serum Calprotectin biomarker, measures activated neutrophils and is now recommended for inclusion in studies on inflammatory bowel disease (IBD). CPa9-HNE may enhance clinical trials by identifying patients with moderate to severe active ulcerative colitis or Crohn’s disease, potentially reducing the need for unnecessary endoscopies. The FDA encourages formal qualification of CPa9-HNE as an enrichment biomarker through analytical validation and data sharing across clinical trials to advance its development as a drug development tool. ➡️ Read the full news and the Letter of Support on the link below: https://lnkd.in/e_7TSxr9 #FDA #IBD #LetterOfSupport #DrugDevelopment #Neutrophils #CPa9HNE

97

2 Kommentarer

Eli Lilly’s and AstraZeneca’s former head of research Dr. Jan Lundberg elected as a new board member Professor Jan Lundberg has been elected as a new board member at the company's annual general meeting in 2024. Professor Jan Lundberg has more than 25 years of experience from leading positions in global pharmaceutical companies, including as global head of research at Astra and then AstraZeneca (1996 – 2009) and global head of research and development at Eli Lilly (2010 – 2018). He has led the development of more than 200 drug candidates, including Alzheimer's and pain, with 30 approved products in several therapeutic areas. Furthermore, Dr. Lundberg co-founded the medtech company Aerocrine, which was later acquired by British Circassia Pharmaceuticals for SEK 1.78 billion in 2015. Before joining Astra, Dr. Lundberg was professor of pharmacology at the Karolinska Institute in Sweden, where he also received his PhD. He also studied medicine at the University of Gothenburg for four years and his research has resulted in over 500 publications in peer-reviewed scientific journals. Read the press release here: https://lnkd.in/d6tWCnUt To the rights issue: https://lnkd.in/d6PHyuRe #biostock #finwire #alzecure #alzheimers #alzheimerfonden #redeye #avanza #nordnet #seb #swedbank #nordea #aktiespararna #privataaffarer #vatorsecurities #erikpenserbank #carlsquare

9

We’re helping fight autoimmune diseases with our next generation biologics. Autoimmune diseases are conditions in which the body's immune system mistakenly attacks its own healthy cells, tissues, or organs, leading to inflammation and tissue damage. Autoimmunity involves intricate signaling pathways with highly potent signaling molecules. At Affibody, we're at the forefront of crafting innovative therapies aimed at preventing these harmful processes. With our cutting-edge technology platform, we can develop drugs that precisely and selectively block inflammation-causing signaling pathways, providing effective treatment options for autoimmune diseases. Learn more about our pipeline: https://lnkd.in/dukR7hcG #antibodies #autoimmunediseases #biotech

30

Alligator Bioscience AB see the replay of the Q2’24 conference call and hear more about the plans for phase 3 studies in H1 2025 for lead product Mitazalimab in pancreatic cancer following strong phase 2 data readouts. CEO Søren Bregenholt also shares his views on a potential partnership deal on Mitazalimab and the opportunities to expand into more indications. Cash burn is still expected to be around SEK 40m for the coming quarters provding Alligator finances to Q1’25. More milestones to come in H2’24 like for instance the phase 1 top line data readout for ALG.APV-527 in solid metastatic cancers expected in Q4’24 Listen to the call here: https://lnkd.in/dcTX7Ain

4

🚀 Partnerships of the week: 1️⃣ Iambic Therapeutics x Lundbeck In a powerful collaboration, Iambic Therapeutics and Lundbeck have teamed up to leverage AI for drug discovery, specifically targeting brain diseases. This partnership aims to combine cutting-edge artificial intelligence with deep scientific expertise to accelerate the development of novel therapeutics for neurological disorders. 👉 Learn more: Link in comments 2️⃣ Evotec x Novo Nordisk Evotec and Novo Nordisk are entering a technology development partnership focused on stem cell-based therapies. Together, they aim to create off-the-shelf cell therapy products for clinical and commercial use, with the goal of advancing breakthrough therapies in regenerative medicine. 👉 Learn more: Link in comments #biotech #pharma #drugdiscovery #AI #stemcelltherapy #innovation #collaboration

31

3 Kommentarer

Financing #drugdevelopment programs can be tricky. 💸 Typically, the stakes are high, the expertise gap is wide, and study timelines are long. So today, we hosted Lundbeckfonden / Lundbeck Foundation to discuss their Frontier Grant program, which provides important financial and interactive support commercial and translational development for therapeutic research. Awardees get mentoring + professional development to boot! Events like this ensure Syddansk Universitet - University of Southern Denmark researchers talk to financers EARLY and learn what #venturecapital investors will want to see/know down the commercial development road. Thank you to Paul E.G. Kristjansen, Liane Dupont, and Kevin Dolowy Dalgaard for coming to see us. Thank you to Jakob Møller-Jensen, Uffe Holmskov + all the motivated researchers from Syddansk Universitet - University of Southern Denmark who joined the discussion! .... + Well done Lene Aarenstrup Nielsen + Liv Thomsen for pulling off another productive partner event! #grants #venturecapital #lifescience #biotech #danskbiotek #therapeutics SDU RIO

28

1 Kommentar